BERKELEY HEIGHTS, N.J., Aug. 31, 2026 (GLOBE NEWSWIRE) -- Kalaris Therapeutics, Inc. (NASDAQ:KLRS) ("Kalaris"), a clinical-stage biopharmaceutical company dedicated to the development and commercialization of
Patient dosing is ongoing in the Phase 1b/2 study of TH103; preliminary data anticipated in 1H 2027 Potential Phase 3 clinical trials remain on track for initiation by year-end 2027 $93.5 million in cash, cash
STAMFORD, Conn., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Abbott Cooper PLLC is investigating potential legal claims on behalf of stockholders of Kalaris Therapeutics, Inc. (NASDAQ:KLRS), formerly AlloVir, Inc.
Strategic finance leader with over 20+ years of experience in the biotechnology space CFO hire bolsters Kalaris’ leadership team and supports continued growth of the company as it enrolls its Phase 1b/2 study of TH103
Data from the expanded cohorts reinforce the positive BCVA, OCT, pharmacokinetic and time-to-retreatment findings observed in the original cohorts Enrollment in the Phase 1b/2 multiple-ascending dose trial of TH103
BERKELEY HEIGHTS, N.J., July 06, 2026 (GLOBE NEWSWIRE) -- Kalaris Therapeutics, Inc. (NASDAQ:KLRS) ("Kalaris"), a clinical-stage biopharmaceutical company dedicated to the development and commercialization of
BERKELEY HEIGHTS, N.J., June 23, 2026 (GLOBE NEWSWIRE) -- Kalaris Therapeutics, Inc. (NASDAQ:KLRS) ("Kalaris"), a clinical-stage biopharmaceutical company dedicated to the development and commercialization of
BERKELEY HEIGHTS, N.J., June 12, 2026 (GLOBE NEWSWIRE) -- Kalaris Therapeutics, Inc. (NASDAQ:KLRS) ("Kalaris"), a clinical-stage biopharmaceutical company dedicated to the development and commercialization of
Patient screening now underway in the Phase 1b/2 study with the latest drug product batch on track to be available to support upcoming dosing; preliminary data anticipated in 1H 2027 Planned Phase 3 clinical trials
Positive initial data reported from Phase 1a Single Ascending Dose study in nAMD in December 2025; preliminary data from ongoing Phase 1b/2 study expected in 1H 2027 Intend to initiate Phase 3 clinical trials by
BERKELEY HEIGHTS, N.J., Jan. 28, 2026 (GLOBE NEWSWIRE) -- Kalaris Therapeutics, Inc. (NASDAQ:KLRS) ("Kalaris"), a clinical-stage biopharmaceutical company developing differentiated therapies for retinal diseases, today
BERKELEY HEIGHTS, N.J., Dec. 17, 2025 (GLOBE NEWSWIRE) -- Kalaris Therapeutics, Inc. (NASDAQ:KLRS) ("Kalaris"), a clinical-stage biopharmaceutical company dedicated to the development and commercialization of
TH103 showed mean 10-letter gain in visual acuity and rapid, robust anatomic improvement at Month 1, following a single injection TH103 was generally well tolerated, supporting further dose escalation beyond 2.5 mg
Phase 1a Single Ascending Dose trial remains on track for initial clinical data to be reportedby year end 2025 Phase 1b/2 Multiple Ascending Dose trial currently enrolling, intended to inform dose selection for
Highly experienced biopharma financial officer joins leadership team CFO hire bolsters Kalaris' leadership team and supports continued growth of the company as it enrolls its Phase 1b/2 study in treatment naïve nAMD
